Back to the Top 100
Isomorphic Labs logo

Rank 3Biotech & Discovery

Isomorphic Labs

Reimagines drug discovery from first principles using deep learning models to predict molecular structures.

Visit website
Signal Score
94.8
Total raised
$100M
Stage
Growth
Founded
2021
Headquarters
London, UK
Region
Europe

Their signal

An Alphabet spinoff powered by DeepMind's AlphaFold, Isomorphic Labs is pioneering AI-driven de novo drug design, securing high-profile commercial partnerships with major pharmaceutical leaders like Eli Lilly.

Signal Score 94.8editorial estimate, see how it is built
Capital (25% weight)96

Total raised, quality of investors and recency of the last round.

Growth (25% weight)92

Revenue trajectory, customer count, hiring and market pull.

Clinical & regulatory (20% weight)95

Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.

Team (15% weight)98

Founder track record, clinical depth on the bench and technical leadership.

Online visibility (15% weight)94

Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.

Also in Biotech & Discovery

Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.